COMPARE · Reviewed July 9, 2026
ANIP vs CPRX
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 83.7, CPRX scored 84.6 — CPRX leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
83.7
$83.78 · $1.9B
Score gap
0.9
CPRX leads
CPRX
Catalyst Pharmaceuticals, Inc.
84.6
$31.47 · $3.9B
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
CPRX
64
Qualityreturns · margins · balance sheet
91
100
Growthrevenue & earnings expansion
100
91
Valuevaluation vs sector peers
67
ANIP and CPRX split the three pillars evenly.
Fundamentals, head-to-head
ANIP
CPRX
$191mC
FCF
$208mC
+43.8%A
Rev
+19.8%B+
1.12C
D/E
0.00A
21.4xB+
P/E
18.2xA-
0.49A
PEG
0.92B+
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
CPRX
47% below
Price vs fair valuelower is cheaper
7% above
+64%
1-yr DCF upside
-3%
+89%
5-yr DCF upside
-7%
+132%
10-yr DCF upside
-11%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
CPRX
Why this score
- Durable high returns
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.9b. 16% off the 52-week high of $99.50. Revenue growing +44% — in hypergrowth territory. PEG 0.49 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $112.71 (implying +35% upside).
Moat
ROE 16% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Free cash flow runs well ahead of reported net income — non-cash charges (depreciation, intangible amortization) are holding down GAAP earnings while cash generation stays strong. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
CPRXCatalyst Pharmaceuticals, Inc.
Why now
Biotechnology · market cap $3.9b. 3% off the 52-week high of $32.56. Revenue growing +20%, comfortably above the S&P median. PEG 0.92 — paying under fair value for the growth rate. 3 sell-side analysts publish a mean 1-yr target of $31.67 (implying +1% upside).
Moat
Net margin 37% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 22% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.